2007
DOI: 10.1002/jmri.21196
|View full text |Cite
|
Sign up to set email alerts
|

Improved tumor vascular function following high‐dose epidermal growth factor receptor tyrosine kinase inhibitor therapy

Abstract: Purpose: To determine if inhibitors of the human growth factor receptor (HER) family can be used to enhance tumor vascular permeability and perfusion and optimize the efficacy of cytotoxic chemotherapeutics. Poor tumor vascular function limits the delivery and efficacy of cancer chemotherapeutics and HER family tyrosine kinases mediate tumor-endothelial signaling in both of these compartments. Materials and Methods:BT474 human breast cancer tumors were established in mice and the biologic effects of the HER ty… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
18
0

Year Published

2009
2009
2022
2022

Publication Types

Select...
7
2

Relationship

0
9

Authors

Journals

citations
Cited by 20 publications
(19 citation statements)
references
References 38 publications
1
18
0
Order By: Relevance
“…Drugs targeted against the vascular endothelial growth factor (VEGF) pathway, such as bevacizumab, are being utilized in the clinic [4]. However, data suggest that other anti-cancer agents, including chemotherapy and targeted agents such as EGFR inhibitors, might also have effects to decrease the quantity or functionality of tumor vasculature [5-10]. …”
Section: Introductionmentioning
confidence: 99%
“…Drugs targeted against the vascular endothelial growth factor (VEGF) pathway, such as bevacizumab, are being utilized in the clinic [4]. However, data suggest that other anti-cancer agents, including chemotherapy and targeted agents such as EGFR inhibitors, might also have effects to decrease the quantity or functionality of tumor vasculature [5-10]. …”
Section: Introductionmentioning
confidence: 99%
“…DCE-MRI is considered a pharmacodynamic endpoint because this particular method of image acquisition measures the vascular effects of drug treatment [9]. DCE-MRI has the potential to monitor the early activity of TKIs in clinical trials [10].…”
Section: Introductionmentioning
confidence: 99%
“…Given that hypoxic tumors are resistant to radiation therapy and that heterogeneous tumor blood flow may affect the efficacy of systemic chemotherapeutics, methods for assessing tumor blood flow/perfusion characteristics, as a marker of hypoxia, may allow clinicians to predict response [62] or alter the existing therapy or select a more aggressive alternative therapeutic approach. Furthermore, with the increasing use of antiangiogenic agents, that may not cause dramatic reduction in tumor volume, DCE-MRI can provide a quantitative method of monitoring and characterizing treatment response [60,[63][64][65][66].…”
Section: Tumor Physiology and Microenvironment By Dce-mri Dw-mri Cementioning
confidence: 99%
“…Predictor of anti-vascular therapy response [60], [62][63][64][65][66], [69][70][71][72][73], [182][183][184][185] [191]…”
Section: Mrimentioning
confidence: 99%